Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis.
Yuki FurukawaSaki OguroSatomi ObataTasnim HamzaEdoardo G OstinelliKiyoto KasaiPublished in: Psychiatry and clinical neurosciences (2022)
One to two milligrams of brexpiprazole as augmentation treatment may achieve an optimal balance between efficacy, tolerability, and acceptability in the acute treatment of antidepressant-refractory depression. However, the small number of included studies limit the reliability of the results. Further research is required to validate the findings.